title: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
abstract: Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.
authors.affiliation: Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. rpiekarz@nih.gov
authors.forename: R L
authors.initials: RL
authors.lastname: Piekarz
authors.forename: R
authors.initials: R
authors.lastname: Robey
authors.forename: V
authors.initials: V
authors.lastname: Sandor
authors.forename: S
authors.initials: S
authors.lastname: Bakke
authors.forename: W H
authors.initials: WH
authors.lastname: Wilson
authors.forename: L
authors.initials: L
authors.lastname: Dahmoush
authors.forename: D M
authors.initials: DM
authors.lastname: Kingma
authors.forename: M L
authors.initials: ML
authors.lastname: Turner
authors.forename: R
authors.initials: R
authors.lastname: Altemus
authors.forename: S E
authors.initials: SE
authors.lastname: Bates
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D047630:Depsipeptides; D004791:Enzyme Inhibitors / Q000494:pharmacology; D056572:Histone Deacetylase Inhibitors; D006657:Histones / Q000097:blood / Q000378:metabolism; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic; D012074:Remission Induction; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D010456:Peptides, Cyclic; C087123:romidepsin